Navigation Links
Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value
Date:2/26/2009

ganizations and suppliers involved in naproxcinod's clinical development and manufacturing activities. At this time, the cost of sales corresponds to the expenses incurred by NicOx in performing research activities under the contracts signed with Pfizer and Merck. On December 31, 2008, the Company employed 97 people in research and development, compared to 84 people at the same date in 2007.

In 2008, administrative and selling expenses totaled EUR11.4 million compared to EUR11.3 million in 2007. General and administrative expenses were EUR6.6 million in 2008 compared to EUR6.8 million in 2007 and include personnel expenses in administrative and financial functions, as well as the remuneration of corporate officers, including stock option, bonus share and warrant attributions. In 2008, selling expenses totaled EUR4.8 million, compared to EUR4.5 million in 2007, and correspond to the market analysis activities for naproxcinod, as well as the business development and communication activities of the Company. The Company anticipates a significant increase in its selling expenses in the future, due to activities linked to the commercial launch preparation for naproxcinod. On December 31, 2008, the Company employed 36 people in its selling, general, and administrative departments, compared to 33 people on December 31, 2007.

Other income

Other income totaled EUR3.8 million in 2008, compared to EUR3.9 million in 2007. Other income corresponds mainly to the operational subsidies from the research tax credits which were previously deducted from research and development expenses until December 31, 2007.

Operating result

In 2008, the operating loss totaled EUR79.2 million, compared to EUR37.2 million in 2007. This situation is explained by the considerable increase in operating expenses during 2008 and by the significant decrease in revenues recognized in 2008 as indicated above.


'/>"/>
SOURCE NicOx
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Arpida Announces Full Year 2008 Financial Results
2. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
4. American Oriental Bioengineering, Inc. to Report Fourth Quarter and Full Year 2008 Financial Results on March 9, 2009
5. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
6. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
7. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
8. Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results
9. Adolor Corporation to Host Investor Conference Call to Report 2008 Financials and Provide an Update on the Launch of ENTEREG(R) (alvimopan)
10. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
11. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... e2b teknologies , a premier Sage ... Ohio, today announced a leading independent multi-specialty physician group ... to the latest version of Sage 100 ERP ... its kind in the region, the organization has an ... efficiency and data accessibility are paramount to their ongoing ...
(Date:3/4/2015)... BALTIMORE , March 4, 2015 In ... at the UPMC Center for Health Security review the ... that can be used as bioweapons. The article, "Clinical ... online today on the website of the New ... authors—Amesh Adalja, Eric Toner , and Tom Inglesby—review ...
(Date:3/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/nqxxt3/biomarkers ... new report "Biomarkers - Technologies, Markets and ... This report follows the broad definition of a ... measured and evaluated as an indicator of normal ... responses to a therapeutic intervention. Tests based on ...
(Date:3/4/2015)... 2015 Proove Biosciences , ... is excited to announce the launch of their ... the Management of Pain”. , The continuing medical ... the next year. The focus of the program ... inadequate pain treatments, integrate appropriate pain management techniques, ...
Breaking Biology Technology:Physician Group Practice Chooses e2b teknologies to Support Its Upgrade to Sage 100 ERP 2014 2Latest Clinical Information On Bioterrorism Threats 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3
... the manufacturer of,medical aesthetic lasers, announced today that ... Sanders Morris Harris Group (Nasdaq: SMHG ), ... fund expansion into,new markets., The additional funding ... channel expansion into the market of about 300,000 ...
... Sept. 19 Tengion Inc., a clinical,stage regenerative ... neo-tissues, today announced that it was one of ... innovation and,success at the 35th Anniversary Celebration of ... Partner at Quaker BioVentures -- a,venture capital investor ...
... Thirty seven medical,experts in psychiatry from across ... take urgent action to optimize services for people ... schizophrenia or bipolar,disorder(i)., Professor W. Wolfgang Fleischhacker, ... Severe Mental Disorders: Clinical,Policy, and Research Challenges which ...
Cached Biology Technology:Aerolase Retains SMH Capital Inc. to Advise on Corporate Expansion 2Tengion Featured as Model of Innovation and Success at 35th Anniversary Celebration of the National Venture Capital Association 2Global Psychiatrists Unite to Improve Services in Mental Health 2Global Psychiatrists Unite to Improve Services in Mental Health 3
(Date:2/5/2015)... 2015 Despite a lack of advancements ... as consumer electronics, automotive, storage and telecommunication has ... (SMT) screen printers. Innovations in electronics and conversion ... the adoption curve up. Meanwhile, sale volumes of ... dispensers are indispensable in the production of complex ...
(Date:1/22/2015)... Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source of ... of its new website design. "When we launched ... says Peter O,Neill , founder and CEO of FindBiometrics. ... needs involvement from the key players on a very broad ...
(Date:1/22/2015)... 15, 2015  BellBrook Labs, a leader in high ... launch of a TR-FRET (time resolved Forster resonance ... Assay, a high throughput screening assay for glycosyltransferases ... allow for sensitive detection of hundreds of human ...
Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... produce approximately 25 percent of the total catch by ... With such a substantial portion of the nations economy ... the Gulf of Mexico region it comes as ... scrutinized by researchers across the globe. While some recent ...
... the tanker Jessica, loaded with 150,000 gallons of fuel, struck ... one of the most precious, famous and fragile ecosystems on ... numbers of unique species of flora and fauna renowned through ... of evolution by natural selection. While scores of wildlife ...
... Mo. Craniosynostosis, the premature fusion of the skull, is ... the past several years, physicians have used two procedures to ... from ear to ear, strip back the scalp of the ... had fused. The other procedure required a small incision near ...
Cached Biology News:LSU researchers challenge analyses on sustainability of Gulf fisheries 2First wind turbines on Galapagos Islands will halve diesel imports, reduce risk of future oil spills 2First wind turbines on Galapagos Islands will halve diesel imports, reduce risk of future oil spills 3First wind turbines on Galapagos Islands will halve diesel imports, reduce risk of future oil spills 4Craniosynostosis minimally invasive surgery holds more promise than old procedure 2
...
Sterile detoxified 10% bovine serum albumin (BSA) in Iscoves MDM. This BSA has been selected to support the optimal colony growth of human hematopoietic progenitor cells in methylcellulose-based medi...
... high-performance ICP-MS system designed for flexibility and ... II off-axis ion lens, true hyperbolic quadrupole ... handle the widest range of sample types ... now includes as standard Agilents unique ShieldTorch ...
... to the DH-2000, except that it uses a ... wavelength range and comes with a shutter (controlled ... 5 Hz) The DH-2000 Deuterium Tungsten ... deuterium and tungsten halogen light sources in a ...
Biology Products: